glp-1 receptor agonist with dpp-4 inhibitor combination not recommended Table 2 from DPP- 4 Inhibitors in the Management of Type 2 Diabetes Mellitus do not combine dpp-4 inhibitors

The SUPRPASS-4 trial (262), involving 2002 participants with high-risk cardiovascular profiles followed for up to 104 weeks, showed no difference in 4-MACE events (cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina) with tirzepatide compared to insulin glargine (HR 0.74

P.VelazquezE

This switch is essential in inflamed synovium because it lowers inflammation markers such as IL-6 and tumor necrosis factor-alpha (TNF-) [87]

JAMA (2018) 319:24154

The general guidance for GLP-1 injections applies to both medications

136,169,170 With the accumulation of more clinical data and the development of new drugs, these treatment options are expected to provide more effective and comprehensive treatment choices for diabetes patients